MOH Response to Claims Regarding Use of Ivermectin Could Prevents All COVID-19 Deaths

Ivermectin is an anti-parasitic drug mostly used in veterinary medicine, especially treating worm infestations. In April 2020, researchers using laboratory methods showed that Ivermectin can also inhibit the replication of SARS-CoV-2, the novel virus that causes COVID-19 illness. Since then, many authors relying on findings from small studies and case series have suggested the potential use of Ivermectin against COVID-19. Yet the recommendation for the ‘off-label’ use of Ivermectin in COVID-19 has been controversial since the beginning.

Firstly, many Ivermectin studies had limitations including small sample size, non-controlled study designs or that the drug was used as add-on treatment. Therefore this had confounded the effect of Ivermectin, if any. In January 2021, a placebo-controlled randomized trial involving 24 non-severe COVID-19 patients did not manage to show reduction in the proportion of PCR positive patients at day 7 post Ivermectin 400 mcg/kg single oral dose treatment. The authors of the pilot study, published in EClinical Medicine (Lancet), opinionated that larger trials may be needed to understand the effects of Ivermectin. In March this year, the Journal of American Medical Association (JAMA) published a randomised-controlled trial involving 476 adults with mild COVID-19 disease given a 5-day course of Ivermectin. The results showed that there was no significant improvement in COVID-19 symptoms resolution time. Whilst Ivermectin may have some anti-viral and anti-inflammatory effects, the evidence remains inconclusive.

Read further at: https://kpkesihatan.com/2021/05/16/moh-response-to-claims-regarding-use-of-ivermectin-could-prevents-all-covid-19-deaths/

COVID-19 in Malaysia : Numbers at a Glance as of 16th. May 2021, 12 pm

#COVID19
#KitaMestiMenang
#sihatmilikku

Telegram SIHAT MILIKKU (MyHEALTHKKM)
t.me/sihatmilikbersama
(Saluran Rasmi Bahagian Pendidikan Kesihatan,
Kementerian Kesihatan Malaysia)

Kenyataan Akhbar KPK 16 Mei 2021 – Situasi Semasa Jangkitan Penyakit Coronavirus 2019 (COVID-19) di Malaysia

Kementerian Kesihatan Malaysia (KKM) ingin memaklumkan status terkini kes COVID-19 di Malaysia sehingga 16 Mei 2021 (jam 12:00 tengah hari);

• Kes sembuh : 3,990 kes (426,319 kes kumulatif, 90.7%);
• Kes baharu : 3,780 kes (470,110 kes kumulatif);
• Kes import : 2 kes (2 warganegara);
• Kes tempatan : 3,778 kes [3,441 warganegara (91.1%); 337 bukan warganegara (8.9%)];
• Kes aktif : 41,889 kes;
• Kes yang memerlukan rawatan di Unit Rawatan Rapi (ICU) : 520 kes;
• Kes memerlukan bantuan pernafasan : 272 kes;
• Kes kematian : 36 kes (1,902 kes kumulatif, 0.40%; 35 warganegara, 1 bukan warganegara);
• Jumlah kluster : 1,887 kluster;
• Jumlah kluster baharu : 11 kluster;
• Jumlah kluster yang telah tamat :1,417 kluster; dan
• Jumlah kluster aktif : 470 kluster.

Terdapat 36 kes kematian pada hari ini yang melibatkan lapan (8) kes di Selangor, enam (6) kes di Pulau Pinang, masing-masing lima (5) kes di Sarawak dan Kedah, empat (4) kes di WP Kuala Lumpur, tiga (3) kes di Perak, masing-masing dua (2) kes di Negeri Sembilan dan Terengganu serta satu (1) kes di Pahang.

Untuk kenyataan penuh, baca lanjut di: https://kpkesihatan.com/2021/05/16/kenyataan-akhbar-kpk-16-mei-2021-situasi-semasa-jangkitan-penyakit-coronavirus-2019-covid-19-di-malaysia/